• Soft·Ox Solutions - New ways of eradicating infections and fighting antimicrobial resistance.
  • Patented and clinically proven.
What are you looking for?

Press Releases & Updates

Important Press Releases & Company Updates

Regulated News

SoftOx Solutions AS (SoftOx) has previously been refused on a request for a transitional arrangement from the Norwegian Environment Agency for its hand
disinfection products. In this context, the company has requested an assessment and a clarifying statement from the European Commission.

Will be able to deliver on the National Hospital Tender (HINAS) and European markets
The company’s interpretation of the Biocidal Regulations is in line with the Commission’s statement regarding the possible transitional arrangements for the
company’s hand and surface disinfectants.

“This is very good news for SoftOx. In our opinion the European Commission’s assessment will enable us to make our products available on the market and we will be able to fulfil our obligations in accordance with the HINAS agreement. The European Commission’s analysis and assessment means that SoftOx can, if the company wants to, go to all European markets with its disinfectant products for hand and surface”, says CEO Geir Almås.

“We are ready to meet increased demand”
The company have a pending application in process in the Norwegian Environment Agency for approval of the company’s hand and surface disinfection products. The transitional arrangement described by the EU Commission gives the company the opportunity to have the hand and surface products on the market until final approval of the pending application is available.

“This is a scenario we have prepared for by buying 50 percent of Ose Water. We are ready to meet potential increased demand from major European markets”,
according to Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

The Research Council has allocated approximately 2.4 MNOK to SoftOx Solutions AS’s subsidiary SoftOx Defense Solutions (SDS) for the completion of a PhD for the development of a multi-product for the Armed Forces. The PhD program is a 3rd year program in collaboration with the Norwegian Defense Research Establishment (FFI) and the Department of Pharmacy at the University of Oslo. The companies will research and develop a multi-product for disinfection and wound wash, increasing the operational capability of Norwegian soldiers.

– The grant is highly appreciated and it is important for further development of the project “multiproduct” that The Research Council provides this award, says
CEO of SoftOx Defense Solutions, Rune Jomaas. The PhD candidate is already active working both at the Norwegian Defense Research Establishment and the
Department of Pharmacy.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CEO Rune Jomaas of SoftOx Defense Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

SoftOx Solutions AS works in a pan-European consortium to develop military countermeasures against chemical substances, biological agents, radioactive substances and nuclear material, so-called CBRN substances, for use in the Norwegian Armed Forces and the EU’s military forces.

In April 2021, SoftOx entered a three-year research collaboration with the Norwegian Defence Research Establishment (FFI) to improve the operational capability of Norwegian and international soldiers. In this connection, the subsidiary SoftOx Defense Solutions AS (SDS) was established. Based on SoftOx technology, SDS develops military applications for the Norwegian Armed Forces, the EU’s military forces, NATO and the US Armed Forces. The work with the consortium lies in this company.

The consortium is led by France and the application is sent to the European Defense Fund (EDF) on 9 December 2021. The research work is based on SoftOx’s technology as a basis for the development of military countermeasures and has a total estimated total of approx. NOK 500 million (Euro 50 million). SDS’s share is estimated at approximately NOK 120 million (Euro 12 million) to develop a military inhalation solution for the EU. The company will apply to EDF to cover 80 percent of the costs associated with the project, ie NOK approx. 96 million (Euro 9.6 million). The Norwegian contribution must account for the rest, ie approx. NOK 24 million (Euro 2.4 million)

The Ministry of Defense has decided to guarantee 40 percent of the Norwegian contribution through so-called co-financing and has allocated SDS a total of 10.6 MNOK to the project.

– This is a sign of quality and a declaration of confidence from the Ministry of Defence. We have big plans for SDS in the future, says CEO Geir Almås of SoftOx Solutions.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

SoftOx Solutions AS is pleased to invite investors, analysts and other stakeholders to our Strategy and Capital Markets Day, including Q3 2021 results on Wednesday the 17th of November 2021 at 09.00 to 12.00 (CET).

Schedule:

09.00-09.10     Opening with CEO Geir Almås

09.10-10.00     Technology platform and business strategy

10.00-11.30     Program areas for development

11.30-11.45     Finance

11.45-12.00     Q&A

The event will be held in-person at Technopolis, Martin Linges Vei 25, 1364 Fornebu, Norway. It will also be streamed live.

Please register for the event, before 15th of November 2021, by sending an email to ir@soft-ox.com

The Q3 2021 results will be released at 07:00 (CET) on Wednesday November 17, 2021. The interim report and related materials will be made available on: https://soft-ox.com/financial-calendar-reports/.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Mundal Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

(SoftOx) We are pleased to announce that the first patient has been recruited to the SBE-01 clinical study. After having experienced unforeseen challenges regarding access to and availability of eligible patients, mainly due to the nationwide nurse strike in Denmark, it is reassuring that the study team has now been able to screen and select several patients for the study, says Glenn Gundersen, Chief Medical Officer in SoftOx Solutions.

SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the SoftOx’ lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, Glenn Gundersen
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

SoftOx Solutions AS (SoftOx) have announced today that the first subject has received SoftOx Inhaled Solution (SIS), in the first-in-human Phase 1 trial. SIS is an aerosolized pan-antimicrobial product intended for the treatment of upper and lower respiratory tract viral and bacterial infections. The trial is part of a development program for the use of SIS in the treatment of SARS-CoV-2 (COVID-19) and other respiratory tract infections, and is a collaboration between SoftOx and University of Copenhagen.

The first subject received a single administration of low dose SIS. Healthy volunteers will receive three escalating doses of SIS or placebo, nebulised as a single dose once, twice or four times daily for 5 days.

SIS is a stabilised solution of hypochlorous acid that can be aerosolised and inhaled. The antimicrobial properties of hypochlorous acid are well described, and endogenous production of hypochlorous acid is one of the key elements involved in host immunity from infectious disease.

“The SoftOx technology platform is a stabilised formulation of hypochlorous acid that permits aerosolization using a jet nebulizer” says Dr Christopher Burton, Chief Medical Officer for SIS. “The SIS-01 trial will evaluate safety and tolerability of three different concentrations administered up to four times daily, which will provide the basis for future studies evaluating efficacy in COVID-19 and other respiratory tract infections.”

SIS-01 (EudraCT No.: 2020-004462-19) is a single-centre, randomised, double-blind, placebo-controlled, study will explore the safety and tolerability of single and multiples doses of inhaled nebulised SIS in healthy subjects.

“This is another important milestone in the development of a pharmaceutical product for which there is a huge unmet need,” says Geir Almås, CEO.

“Society faces a growing threat of new emergent viral strains and increasing antimicrobial resistance to currently available treatments. SIS has the potential to fill that need.”

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, SIS, Christopher Burton
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

The board of SoftOx Solutions AS has entered into a loan agreement with Almhaug Bolig AS, where the main shareholder is one of the shareholders. Almhaug Bolig AS will provide the company with a short-term loan of NOK 15 million.

“In the last year, the company has experienced some delays both in connection with regulatory processes with the authorities and in the implementation of certain clinical studies. To compensate for the liquidity burden caused by these delays, the company’s main shareholder has given the company a loan of NOK 15 million. Additional supply of liquidity may be considered if desired. The company is grateful that the company’s main shareholder shows his support for the company I this situation. It is important for the company to have owners who are dynamic and support the company financially in such situations”, says CEO Geir Almaas of SoftOx Solutions.

“We work with several exciting processes. Among other things, we recently received approval from the Danish Medicines Agency to start SIS (SoftOx Inhalation solution) studies in humans. For us, this is a very exciting race, which we have high expectations for”, Almås continues.

The loan has a maturity of 12 months and is not interest-bearing. The loan will in principle be repaid in cash, but until the maturity of the loan, Almhaug Bolig AS will have the right to convert the loan into equity in the company by issuing new shares at a price equal to the volume- weighted average share price in the last five days before entering into the agreement, minus five percent, NOK 38,551 per share. The board is of the opinion that the discount is commercially justified as the loan is interest-free. If the company carries out a share issue before the loan matures or is converted into shares, Almhaug Bolig AS will have the right to convert the loan into shares at the same price per share as the subscription price in such an issue.

New shares that may be issued in connection with the conversion right will be approved by the company’s board in accordance with the authorization given by the annual general meeting on 13 April 2021. The board has assessed the loan agreement and the right of conversion in relation to the rules on equal treatment and is of the opinion that there is a valid reason for differential treatment.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine M. Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

OSLO – October 6, 2021: SoftOx Solutions AS (SoftOx) have announced today that the Danish Medicines Agency (DKMA) approved the Phase 1 clinical trials for SoftOx Inhaled Solution (SIS), an aerosolized antimicrobial product intended for the treatment of upper respiratory tract infections (e.g., influenza and common colds) and lower respiratory tract infections (e.g., pneumonia and bronchitis).

“SIS would be a game changer in the treatment of viral and bacterial infections in the respiratory tract”, says CEO Geir Almås at SoftOx Solutions.

“Soon commencing human trials”

The Phase 1 trial is part of a development program for the use of SIS in the treatment of respiratory tract infections starting with SARS-CoV-2 (COVID-19) infections. This trial is scheduled to commence in autumn 2021, in Denmark.

“We are pleased to have satisfied the Danish Medicines Agency requirements, and that we will soon commence this first-in-human trial of SoftOx Inhaled Solution”, says Dr Christopher Burton, Chief Medical Officer for SIS.

SIS is a stabilised solution of hypochlorous acid that can be aerosolised and inhaled. The antimicrobial properties of hypochlorous acid are well described, and endogenous production of hypochlorous acid is one of the key elements involved in host immunity from infectious disease.

“Hypochlorous acid is extremely effective in killing viruses and bacteria in vitro. Up until now, the problem has been maintaining hypochlorous acid in a stable form until delivery to the target tissues,” says Dr Burton.

First major step
SIS-01 (EudraCT No.: 2020-004462-19) is a single-centre, randomised, double-blind, placebo-controlled study, the study will explore the safety and tolerability of single and multiples doses of inhaled nebulised SIS in healthy subjects.

“This is the first major step in the development of a pharmaceutical for treatment of the respiratory tract based on SoftOx Solutions proprietary technology for the stabilisation of hypochlorous acid,” says Almås.

“SIS would be a game changer in the treatment of viral and bacterial infections in the respiratory tract. SIS is particularly relevant in the context of the current pandemic and for future epidemics and pandemics, and the emerging threat of antimicrobial drug resistance”, continues Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CMO, SIS, Christopher Burton
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Update regarding the ongoing application process for national approval of biocidal products (disinfection products) in Norway (with reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on September 22, 2021).

The Ministry of Climate and the Environment has not upheld the appeal against a decision to reject the application for approval in parallel mutual recognition of SoftOx disinfection. Pending a decision from Sweden, SoftOx must therefore temporarily suspend the sale of SoftOx hand disinfectant. When SoftOx is successful in Sweden, the product will be able to be replaced on the market in Norway.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Update regarding the ongoing application process for national approval of biocidal products (disinfection products) in Norway (with reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on March 29 and September 17, 2021).

The Ministry of Climate and the Environment has not upheld the postponed implementation of whether there should be a deadline in Norway for SoftOx to suspend sales by 3 October 2021, for SoftOx disinfection based on active chlorine released from sodium hypochlorite.

-We do not understand this decision. It is important to emphasize that this has nothing to do with the quality of and clinical documentation of the product, says CEO Geir Almås in SoftOx.

The notice concerns the application for disinfection based on active chlorine released from sodium hypochlorite, where there has been an ongoing appeal process in the Ministry of Climate and Environment regarding the approval of SoftOx disinfection. This application was rejected by KemI in Sweden, and has been appealed to the Land and Environmental Courts in Sweden. Pending a decision from Sweden, SoftOx has applied to the Ministry of Climate and Environment in Norway to remain in the market with the product in question. The current deadline for SoftOx to suspend sales is by October 3, 2021, with the possibility of continued use for a period of six months thereafter. SoftOx has now received a rejection of the request for deferred implementation of decisions. It is pointed out, however, that when SoftOx is upheld in Sweden, the product will be able to be put back on the market in Norway.

The Ministry justifies its refusal on the grounds that: “It is therefore only a question of a temporary loss of revenue” and further writes: “The consequences of the decision are reversible, in the sense that the product can be relaunched on the market.”

– The Ministry has based their decision on process and unfortunately shows little understanding of the importance of keeping the product in the market. The positive is that the Ministry states that the processing of our application will be prioritized, says Almås

SoftOx is now taking a thorough review of the letter from the Ministry of Climate and the Environment and continues the active dialogue with both KemI in Sweden.

– We perceive the dialogue with KemI as very constructive and good, and are optimistic about a positive outcome, says Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Update regarding the ongoing application process for national approval of biocidal products (disinfection products) in Norway (with reference to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on March 29th and July 2. 2021).

The Norwegian Environment Agency has rejected that SoftOx ‘hand disinfection can be covered by a transitional scheme during the period in which the application for product approval is processed. The Norwegian Environment Agency’s interpretation of the regulations is disputed by SoftOx.

– The company does not understand the directorate’s interpretation of the text in the hearing proposal. The situation has been assessed together with leading lawyers. Our opinion is that the NEA here has made a mistake. That SoftOx as a small company should now bear the risk of mistakes made by the Norwegian Environment Agency is perceived as grossly unfair, says CEO Geir Almås of SoftOx Solutions.

SoftOx has two processes towards regulatory authorities associated with its disinfection products: application for approval based on active chlorine released from hypochloric acid and an application for approval based on active chlorine released from sodium hypochlorite. The products are identical, except for a regulatory term for active substance. The fact that the company has two ongoing application processes is because the regulations are complex and that they are interpreted differently from country to country.

SoftOx’s application for approval of the product family in disinfection based on active chlorine released from hypochlorous acid has been submitted in accordance with requirements specified in the Norwegian Environment Agency’s hearing memorandum from March 2021 to new regulations (2021/2157). SoftOx bases its opinion on the fact that there is a transitional arrangement for all disinfection products when the application for approval was submitted within the deadline specified in the hearing memorandum. However, the Norwegian Environment Agency has by letter, and as part of an ongoing dialogue, announced that the that there should be no transitional scheme for products based on active chlorine from hypochlorous acid Product type 1 (hand disinfection).

Without a valid transitional arrangement or temporary permit, SoftOx cannot place its disinfectant products based on this active substance on the market until the Norwegian Environment Agency has approved SoftOx’s new application. SoftOx is now undertaking a thorough review of the letter from the Norwegian Environment Agency and is considering submitting the case to the Ministry of Climate and Environment.

In addition to the application for disinfection based on active chlorine released from hypochlorous acid, there is an ongoing appeal process in the Ministry of Climate and Environment regarding the approval of SoftOx disinfection based on active chlorine released from sodium hypochlorite. This application was rejected by KemI in Sweden, and an appeal is pending in the Ministry of Climate and Environment as to whether there should be a deadline in Norway for SoftOx to suspend sales by October 3, 2021 with the possibility of continued use for a period of six months thereafter.

– We strongly disagree with the Norwegian Environment Agency’s perception of the regulations. We recently won the contract announced by HINAS (Helseforetakenes Innkjøpsservice AS) for hand disinfection products, which shows that our product is best in class. However, we believe in a good and fair treatment from the Ministry of Climate and Environment, to continue to deliver products to our customers. The conclusion is that the regulatory situation is still unclear, says CEO Geir Almås of SoftOx Solutions.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

SoftOx Solutions AS (SoftOx) has entered into an agreement to purchase 50 percent of the shares in Ose Water AS (Ose). According to the agreement, SoftOx will also move all production of disinfection products to Ose and thereby secure reliable production and delivery both nationally and internationally. The agreement ensures production volume at a competitive price with high quality in the years to come.

“This is an important strategic collaboration for us and forms the basis for growth and competitive production in the years to come. Partnering with a competent environment within production and bottling further professionalizes the company,” says CEO Geir Almås of SoftOx.

SoftOx experiences increased demand for the company’s disinfection products, which increases the need for safe and high-quality production.

“Having Ose on the team enables us to comply with the expected demand from Norwegian hospitals, and at the same time the expected increased demand both nationally and also internationally. In addition to the award in a national tender, the company has entered into agreements with a large Norwegian financial group and a Norwegian airline. We hope this is just the beginning, as we now expect other Norwegian customers to demand this product as well as major players are choosing our solution,” says Almås.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

About Ose Water AS
Ose Water AS is a Norwegian natural mineral water producer located in Bygland.
Ose Water is bottled directly from the pure and natural mineral water source
Osekilden at Ose in Setesdal. The factory has a large capacity and several
production lines optimized for different products. For more information about
Ose Water, please visit www.osewater.com

Sykehusinnkjøp HF’s national tender – hygiene products, disinfectants and dispensing solutions for hand disinfectants, soap and cream (HINAS).

SoftOx Solutions AS (SoftOx) has participated in the HINAS tender mentioned here and reports that the company’s hand disinfectant product SafeDes® has been selected and will be listed in Norwegian hospitals as the only alternative to alcohol-based products following the decision in the national tender.

From the evaluation for subcontract 16, hand disinfectants without alcohol (bottles), SoftOx received a top score on the evaluation criteria “properties on
skin” and quality. The product is an alternative for those who have skin problems related to the use of alcohol. The skin does not feel sticky or dry
after use.

This, in combination with a competitive price, is the overall evaluation that SoftOx comes out best in the assessment.

The product has been assessed by the country’s foremost professional expertise on efficacy and safety in disinfection. This is a confirmation of our base
technology, and the decision clearly shows that the product has a place in the health care system. “Winning a national hospital tender is also a very important
reference for the company in other markets, in addition to being a confirmation of our research and our work so far. This award shows that our commitment to
health has been right and provides a good basis for further investment,” says CEO Geir Almås.

The company announces increased investment in its disinfection products. Based on the clear advantages of the products: skin friendliness, effect and security,
we will continue to invest in the categories defense, health, B2B and the transportation industry. We now see that the market responds within these
categories and are experiencing increased demand and sales. However, the Norwegian hospital market is the company’s pilot customer and is not expected to
provide profitability during the first years.

With reference to the stock exchange announcement on 2 July 2021, the company is still working on the basis that company will enter a transitional arrangement in the connection with the new biocidal regulations.

Further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

The first in human study of SoftOx Biofilm Eradicator started as planned at the end of May, but due to the ongoing nurses’ strike in Denmark, we do not expect
to be able to admit patients to the study until the strike is over. The strike is expected to last for approximately 10 weeks. The study is therefore expected
to be somewhat delayed; however, the company will strive to make up for lost time.

This is the phase I study with our lead wound care product, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE, to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine M. Rød, Financial Manager of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

With reference to the stock exchange announcement on March 29, 2021, SoftOx has now submitted a new application for national approval of its biocidal products in Norway. The application addresses the objections raised in the first application and only applies to the Norwegian market.

“The company experienced that the previous application involving Norway, Sweden and Denmark entailed great procedural complexity, which we consider to be a contributing factor to the application being rejected. The new improved application now addresses the weaknesses that were commented on in the previous application. New applications to other countries will be submitted on an ongoing basis. In addition, SoftOx has appealed the rejection of the first
application.” says CEO Geir Almås.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

23 JUN 2021 11:00 CEST

SoftOx Solutions AS (SoftOx) is pleased to announce that the results of the clinical investigation SoftOx Wound Irrigation Solution for acute wounds (SWIS) have been completed. The study, which has been conducted at Bispebjerg University Hospital in Copenhagen, is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (SWIS) compared to Normal Saline (NS) in a human wound model.

The study showed both significant improvement in wound healing and reduction in bacterial burden compared to Normal Saline (NS), positioning the product as superior towards today’s market leaders. Finishing the clinical development program strengthens the SoftOx platform for further product development. The results from the study “SWIS-02” confirm the excellent safety profile of the SoftOx technology platform, also strengthening the documentation of SoftOx hand disinfectant technology with regards to skin friendliness being superior to today’s alcohol-based hand disinfectant. The company now prepares to file their wound irrigation SWIS for final approval as a Medical Device in Europe.

SoftOx Wound Irrigation Solution (SWIS) will become a Medical Device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds. SWIS has the potential to become a favoured alternative to the current wound irrigation solutions on the market which have challenges related to safety (side effects, resistance development) and effect. According to market reports from The Insight Partners, the global market size for wound irrigation solutions was estimated at USD 1.6 billion in 2018, and yearly 190 million wounds is treated in hospitals. Finalization of the SWIS-02 study concludes the clinical evaluation part of the SWIS documentation package. SWIS is expected to be the company’s first CE-marked product for the European market.
Regarding the wound healing capabilities, the study meets its primary endpoint of re-epithelialization (non-inferior to NS) by day 10 with high significance (p<0.0001). Furthermore, early re-epithelialization at day 4 was significantly better than normal saline (mean 57% versus 43%, p<0.0001). Also, overall usability aspects of SWIS handling were reported to be satisfactory.

Once again SWIS demonstrates and confirms previous findings (from SWIS-01) to be safe and well tolerated as a wound irrigation solution for acute wounds and not associated with any major risks. Performance outcomes demonstrate antimicrobial properties with excellent wound healing (re-epithelialization) observations. “This has been a highly successful study with respect to implementation, conduct and outcome and clearly confirms the favourable properties of SWIS as an excellent wound irrigation solution,” says Glenn Gundersen, Medical Director of SoftOx.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

07 JUN 2021 07:00 CEST

SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for the treatment of respiratory tract infections. This has the potential to be a breakthrough in the future treatment of respiratory infections, including viruses, bacteria and fungal infections.

“After an intensive research phase, we are very satisfied that the Danish Medicines Agency (DKMA) considers our documentation positively and has given a conditional approval to be able to start the study”, says Medical Director Glenn Gundersen. “The conditions that have been communicated are related to additional safety data and the company is already working on completing the data as requested. The data will be provided in due time and we believe that the study can be initiated during the autumn.”

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

26 APR 2021 13:58 CEST

In connection with SoftOx Solutions AS reporting for the first quarter of 2021, SpareBank 1 Markets invites to a presentation with the company on Thursday 29 April at 1400.

Date: Thursday 29 April
Time: 14:00 – 15:00
RSVP: Registration to corporateaccess@sb1markets.no

More information:
Access the news on Oslo Bors NewsWeb site

13 APR 2021 19:46 CEST

Det ble avholdt en ordinær generalforsamling i SoftOx Solutions AS den 13. april 2021 kl. 09.00. På grunn av gjeldende restriksjoner mot innendørs arrangementer i Oslo kommune som følge av Covid-19, ble generalforsamlingen kun avholdet som elektronisk møte. 2 671 336 aksjer var representert, tilsvarende 29,14 % av selskapets totale aksjekapital.

Generalforsamlingen vedtok alle forslagene på agendaen i tråd med innkallingen datert 6. april 2021.

Signert protokoll fra generalforsamlingen er vedlagt denne meldingen og vil bli gjort tilgjengelig på selskapets hjemmeside.

More information:
Access the news on Oslo Bors NewsWeb site

09 APR 2021 08:00 CEST

The National Committee of Health Research Ethics (NVK) in Denmark has approved the “SBE-01 study”, a first-in-human, phase I clinical trial in patients with chronic wounds. The study has now received full regulatory clearance to make the
final preparations for initiation. Reference is made to the previous stock announcement of 15th March 2021 regarding authorisation from the Danish Medicines Agency.

“This rapid approval by the relevant regulatory bodies in Denmark will enable us to start the study during Q2-2021” says Glenn Gundersen, Medical Director in SoftOx Solutions.

SBE-01: EudraCT no. 2021-000314-42.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working
to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

06 APR 2021 09:00 CEST

SoftOx Solutions AS will be holding its Annual General Meeting [virtually] on 13 April 2021 at 09:00 hours (CET).

The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: https://soft-ox.com/.

All shareholders are encouraged to exercise their shareholder rights, either by using the enclosed proxy form to provide proxy to the Chairman Melvin Teigen (or the person he appoints), or to attend the general meeting virtually.

Shareholders who wish to participate electronically must register using the attached notice of attendance in order to receive a link to the general meeting. The notice of attendance and proxy form must be received prior to 12 April 2021 at 15:00. Notice of attendance and proxy form are attached to this notice.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

29 MAR 2021 14:32 CEST

With reference to the stock exchange announcement from SoftOx Solutions AS (“SoftOx”) on December 11th, 2020, when SoftOx received information from the Swedish Chemicals Agency that the application for SoftOx Disinfection Products was sufficiently complete to proceed to the final decision-making. Contrary to
this statement, the Swedish Chemicals Agency changed its initial position by rejecting SoftOx application with reference to its latest request for additional testing data.

This implies an estimated six-months delay for SoftOx’s major launch in the European markets, notwithstanding, the Swedish decision does not affect continued sales and marketing in Norway, Sweden and Denmark.

“Based on the information received in December we were confident that our data was sufficient to approve our products. We are surprised by the decision and the justification when the Agency now ask for additional tests”, says CEO Geir Almås of SoftOx Solutions AS.

The request for additional test concerns certain impurities in the formulated disinfectants. SoftOx fundamentally and scientifically disagrees with the Swedish Chemicals Agency’s assessment and request for additional tests for this data. During the evaluation process, SoftOx submitted a series of test data, generated by the accredited third-party laboratory “Sintef”, in which it was confirmed that the concerned impurities does not impact adversely the SoftOx disinfectant products. In support of this, SoftOx has also undertaken additional tests to verify its initial conclusions presented to the competent authorities during the evaluation process. These confirmatory tests (including requested tests) are anticipated to be finalized in November 2021.

Notwithstanding, SoftOx is committed to defend its scientific position and pursue its biocides submission before the national competent authorities. On advice from its scientific experts, SoftOx intends to contest and submit an administrative appeal in Sweden, and to undertake additional regulatory measures to ensure a scientifically viable and sustainable implementation of EU’s biocides regime on SoftOx products.

“SoftOx feels confident that when the requested documentation is available, the application will be duly recognized.” Says Almås.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

23 MAR 2021 15:49 CET

SoftOx Solutions AS (“SoftOx”) is pleased to announce that the enrolment of study participants for the clinical investigation «SWIS-02» has been completed. The study, which has been conducted at Bispebjerg University Hospital is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (“SWIS”) compared to Normal Saline (NS) in a human wound model. It is a confirmative study and last of two clinical studies on “SWIS”.

We are very pleased to have completed this enrolment because of the ongoing lockdown in Denmark, which were affecting our recruitment pace. “With this pivotal trial we are eagerly looking forward to examining and analyse the study data and report on the results later in Q2-2021”, says Glenn Gundersen, Medical Director of SoftOx.

SWIS is under development to become a medical device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

22 MAR 2021 08:30 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on 3rd February 2021 regarding the signing of a letter of intent, the collaboration agreement has now been finalized. SoftOx and the Norwegian Defense Research Establishment (FFI) have signed a collaboration agreement that extends until June 30th 2024. The main focus of the agreement will be on adapting the technology and products the company develops for military purposes both nationally and internationally.

SoftOx is developing a new class of antimicrobial agents, herunder range of wound care products for cleansing, prevention and treatment of wound infections, as well as a product for the treatment of respiratory tract infections. Currently the company delivers alcohol-free hand and surface disinfection products with a broader effect and more unique properties than current products on the market.

The parties have a joint vision to further develop the SoftOx applications to strengthen the military and civilian preparedness against future epidemics, chemical and biological warfare, complexed wound infections and challenging conditions in the respiratory tract.

The plan is to develop a range of military SoftOx products that will be specifically targeted for the needs of the Armed Forces and for civilian purposes in conflict areas. This work will take place in close collaboration with both our national and international civilian and military partners.

“We express high expectations for this collaboration, and we appreciate that FFI has chosen to enter into a collaboration with us. Together we will be improve the safety and the preparedness of our armed forces. We also believe that this agreement will contribute to our products becoming part of the national preparedness in the fight against infections and multi-resistant bacterias, “says CEO Geir Almås in SoftOx Solutions.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Rune Jomaas, Project Director SoftOx Solutions AS.
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About Norwegian Defense Research Establishment Norwegian Defence Research Establishment (FFI) is the prime institution responsible for defence-related research in Norway. The Establishment is the chief adviser on defence-related science and technology to the Ministry of
Defence and the Norwegian Armed Forces’ military organization. The demand for expert and flexible armed forces requires continuous renewal and Norway’s unflagging emphasize on defence technology keeps FFI busy. It is a true challenge to make significant contributions to the development of the Armed Forces – both in its principal national defence role as well as in its various roles as an effective participant in international security operations. Relevant defence research now requires international cooperation. In order to maintain a position at the forefront of science and technology within chosen sectors, FFI collaborates with national and international scientific institutions and industry. The Establishment also has a close working relationship with its partners and customers (Sourse www.ffi.no)

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance” We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

04 MAR 2021 12:28 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 3 March 2021 regarding the preliminary results of the Company’s Subsequent Offering.

The final results confirms the preliminary results reported yesterday. As a result, the Company has received valid subscriptions for in total 971,404 Offer Shares. Hence, the maximum number offered in the Subsequent Offering (181,818 offer shares) will be issued.

The allocation of the offer shares has today been completed based on the allocation criteria set out in the Company’s national prospectus dated 15 February 2021.

Notification of allocated offer shares and the corresponding amount to be paid by each subscriber will be set out in a separate letter to each subscriber, which is expected to be issued during the course of today, 4 March 2021. The payment date for the offer shares allocated is 8 March 2021 and the shares is to be paid for in accordance with the payment instructions set out in the national prospectus and subscription form.

The offer shares may not be transferred or traded until they are fully paid and the share capital increase related to the subsequent offering has been registered with Norwegian Register of Business Enterprises (Nw: Foretaksregisteret). The share capital increase is expected to be registered on or about 12 March 2021. The Offer Shares are expected to be delivered to the subscribers’ respective VPS accounts on or about the 15 March, and be tradeable on Euronext Growth Oslo on or about 16 March 2021.

Following the issuance of the offer shares issued in the Subsequent Offering and the offer shares issued in the employee offering on 24 February 2021, the Company’s share capital will be NOK 183,369.36 divided into 9,168,468 shares, each with a par value of NOK 0.02. See the attached form for notification and publication of allocation to primary insiders.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has acted as legal advisor to as the Company in connection with the Subsequent Offering.

For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS

Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

03 MAR 2021 20:00 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the commencement of the subscription period in the subsequent offering of up to 181,818 new shares at a subscription price of NOK 55 per offer share directed towards eligible shareholders as of 16 December 2020 (as registered in the VPS on 18 December 2020) who did not participate in the private placement successfully completed on the 16 December 2020 (the “Subsequent Offering”).

The subscription period for the Subsequent Offering expired at 16:30 hours (CEST) today, 3 March 2021. Preliminary counting indicates that the Company has received subscriptions for approximately 971 404 offer shares. The final allocation of the offer shares is expected to take place on or about 4 March 2021, in accordance with the allocation criteria set out in the national prospectus.

The final results of the Subsequent Offering will be published shortly after allocation, and letters with allocation information including subscription amount to be paid by each subscriber are expected to be distributed during the course of 4 March 2021.

The payment date for the offer shares allocated in the Subsequent Offering is 8 March 2021, and the delivery date for such shares is expected to be on or about 15 March 2021. The offer shares allocated in the Subsequent Offering are expected to be tradeable on Euronext Growth Oslo on or about 16 March 2021.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has acted as legal advisor to as the Company in connection with the Subsequent Offering.

For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS

Mail: ir@soft-ox.com

Mobile: +47 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

03 MAR 2021 08:00 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the commencement of the subscription period in the subsequent offering of up to 181,818 new shares at a subscription price of NOK 55 per offer share directed towards eligible shareholders as of 16 December 2020 (as registered in the VPS on 18 December 2020) who did not participate in the private placement successfully completed on the 16 December 2020 (the “Subsequent Offering”).

The subscription period for the Subsequent Offering will expire today, on 3 March 2021 at 16:30 (CEST). In order to subscribe for offer shares, SpareBank 1 Markets AS (the “Manager”) must receive a complete and duly signed subscription form within 16:30 today.

Subscription rights that are not used to subscribe for offer shares before the expiry of the subscription period will have no value and will lapse without compensation to the holder.

For further information, please refer to the national prospectus available on the Company’s website www.soft-ox.com, the Manager’s website www.sb1markets.no and that may be ordered from the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

01 MAR 2021 10:37 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the employee offering.

The Board of Directors has resolved to issue a total of 164,348 new shares, each with a nominal value of NOK 0.02, to employees who had applied for shares. The shares were issued under a board authorization granted by the Company’s general meeting on 4 January 2021.

The new shares were issued at a subscription price of NOK 55, resulting in gross proceeds of approx. NOK 9,039,140. The following primary insiders subscribed and were allocated shares in the Employee Offering:

– Melvin Teigen (chairman) has subscribed for 10,000 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Teigen holds 16,000 shares in the Company.

– Geir Almås (CEO) has, through his holding company Hermod Farms AS, subscribed for 36,360 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Almås together with his close associates holds 861 473 shares in the Company.

– Kristine Rød (CFO) has subscribed for 3,637 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Rød holds 3,637 shares in the Company.

– Primary insider Hans Petter Grette has, through his holding company Renholdsprodukter AS, subscribed for 7,288 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Grette together with his close associates holds 90,000 shares in the Company.

– Primary insider Glenn Gundersen has subscribed for 4,550 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Gundersen holds 10,550 shares in the Company.

– Primary insider Elisabeth Ahlmann Ohlsen has subscribed for 200 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Ohlsen holds 200 shares in the Company.

– Primary insider Dag Abrahamsen has, through his holding company Genesis Holding AS, subscribed for 3,636 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Abrahamsen holds 3,636 shares in the Company.

The shares will be delivered through VPS and will be admitted to trading on Euronext Growth Oslo following the registration of the shares in the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

This announcement is made under the Norwegian Securities Trading Act Section 4-2.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

25 FEB 2021 18:38 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the commencement of the subscription period in the planned subsequent offering and parallel employee offering, both consisting of an issuance of up to 181,818 new shares in the Company (the “Subsequent Offering”) (the “Employee Offering”).

Primary insider Claus Seeberg, though his holding company CS Holding AS has committed to subscribe for NOK 293 150 in the Subsequent Offering.

The shares in the Subsequent offering will be allocated by the Board of Directors and issued under a board authorization granted by the Company’s general meeting held on 4 January 2021. The shares in the Subsequent Offering will be allocated by the Board of Directors and will be issued in accordance with the resolution made by the Company’s general meeting held on 4 January 2021.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site